Virtu Financial LLC reduced its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 61.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,981 shares of the company's stock after selling 6,246 shares during the period. Virtu Financial LLC's holdings in Cencora were worth $894,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in COR. Whittier Trust Co. lifted its position in shares of Cencora by 0.6% in the 4th quarter. Whittier Trust Co. now owns 7,856 shares of the company's stock worth $1,765,000 after buying an additional 44 shares during the last quarter. Shepherd Financial Partners LLC lifted its holdings in Cencora by 0.9% in the fourth quarter. Shepherd Financial Partners LLC now owns 5,441 shares of the company's stock worth $1,223,000 after acquiring an additional 46 shares during the last quarter. WASHINGTON TRUST Co raised its position in shares of Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock worth $38,000 after purchasing an additional 46 shares during the period. JFS Wealth Advisors LLC lifted its holdings in shares of Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after purchasing an additional 46 shares during the last quarter. Finally, Cullen Frost Bankers Inc. boosted its position in Cencora by 1.1% during the 4th quarter. Cullen Frost Bankers Inc. now owns 4,463 shares of the company's stock valued at $1,003,000 after purchasing an additional 47 shares during the period. 97.52% of the stock is currently owned by hedge funds and other institutional investors.
Cencora Price Performance
Shares of NYSE:COR traded up $0.83 on Thursday, hitting $272.22. The stock had a trading volume of 156,831 shares, compared to its average volume of 1,376,172. The company has a market capitalization of $52.79 billion, a price-to-earnings ratio of 38.71, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The firm's 50 day moving average price is $252.47 and its 200-day moving average price is $240.68. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $273.55.
Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, equities research analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.
Cencora Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were issued a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.81%. The ex-dividend date of this dividend was Friday, February 14th. Cencora's dividend payout ratio is 31.29%.
Analyst Ratings Changes
Several research firms recently weighed in on COR. Mizuho started coverage on shares of Cencora in a report on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 price objective for the company. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. JPMorgan Chase & Co. lifted their price target on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research report on Friday, January 24th. Wells Fargo & Company increased their target price on shares of Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research note on Friday, March 14th. Finally, Evercore ISI upped their price target on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $280.20.
View Our Latest Report on COR
Insider Buying and Selling
In other news, CAO Lazarus Krikorian sold 2,000 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $260.06, for a total value of $520,120.00. Following the transaction, the chief accounting officer now owns 20,154 shares of the company's stock, valued at $5,241,249.24. This represents a 9.03 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 14,578 shares of Cencora stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total value of $3,928,916.78. Following the sale, the chairman now directly owns 317,913 shares of the company's stock, valued at approximately $85,680,732.63. This trade represents a 4.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,675 shares of company stock worth $8,034,778 over the last three months. 10.80% of the stock is currently owned by company insiders.
Cencora Company Profile
(
Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
See Also
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
